Pablo García‐Pavía
机构：Dr. M.G.R. Educational and Research Institute, Universidad Francisco de Vitoria, Instituto de Salud Carlos III, Spanish National Centre for Cardiovascular Research, Escuela Nacional de Sanidad, Centro de Investigación en Red en Enfermedades Cardiovasculares, Hospital La Paz Institute for Health Research, Hospital Universitario Puerta de Hierro Majadahonda, Centro de Investigación Biomédica en Red, Spanish National Centre for Cardiovascular Research, ERN GUARD-Heart, Centro de Investigación Biomédica en Red de Cáncer · ORCID：0000-0002-5470-2257
发表论文 560 篇 · 总被引 23443 次 · h-index 74
代表论文
- Coramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: A Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial (2025 · Circulation · 被引 15)
- Efficacy of Acoramidis in Wild-Type and Variant Transthyretin Amyloid Cardiomyopathy (2025 · JAMA Cardiology · 被引 5)
- Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy (2025 · Journal of the American College of Cardiology · 被引 2)
- Aficamten in Obstructive Hypertrophic Cardiomyopathy (2025 · Journal of the American College of Cardiology · 被引 2)
- Abstract 4362795: Vutrisiran Improved Outcomes Versus Placebo in Patients with Transthyretin Amyloidosis with Cardiomyopathy and Severe Chronic Kidney Disease: Post Hoc Analysis of HELIOS-B (2025 · Circulation · 被引 2)
- Myosin inhibition in obstructive HCM: A new starting point for therapy (2025 · Progress in Cardiovascular Diseases · 被引 1)